{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:46:04Z","timestamp":1782708364621,"version":"3.54.5"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Advanced biliary tract cancer (BTC) carries a poor prognosis, with limited regional data available. This study evaluated outcomes, treatment patterns, and prognostic factors in a multicenter cohort of patients with\n                      <jats:italic>de novo<\/jats:italic>\n                      advanced BTC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort of 271 patients with\n                      <jats:italic>de novo<\/jats:italic>\n                      advanced biliary tract cancer diagnosed at five tertiary centers in Saudi Arabia (2016\u20132023) was analyzed. Clinical, pathological, treatment, and molecular data were extracted from electronic health records. Overall survival was estimated using the Kaplan\u2013Meier analysis, and prognostic factors were assessed through multivariable Cox regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Systemic therapy was administered to 211 patients (77.9%). Among the entire cohort, 92 patients (33.9%) received second-line therapy, 25 (9.2%) received third-line therapy, and 8 (3.0%) received fourth-line therapy. Median overall survival (OS) was 9.5 months (95% CI, 8.4\u201310.6). On multivariable analysis, inferior OS was independently associated with poor ECOG performance status (PS 4: HR 4.08, P\u00a0=\u00a00.031), age 15\u201339 years (HR 4.44, P &amp;lt; 0.001), extrahepatic cholangiocarcinoma (HR 1.91, P\u00a0=\u00a00.017), cirrhosis (HR 3.13, P\u00a0=\u00a00.004), and elevated CEA (HR 1.92, P\u00a0=\u00a00.003). Patients with disease control had a 71% lower hazard of death (HR 0.29, 95% CI 0.18\u20130.47) and longer median OS (16.0 vs 7.7 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Advanced BTC in Saudi Arabia demonstrates poor outcomes, with survival strongly influenced by performance status, age, tumor site, cirrhosis, and biomarkers. Treatment exposure was limited, with only one-third receiving second-line therapy, highlighting the urgent need for expanded access to immunotherapy and molecular profiling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1712037","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:26:48Z","timestamp":1782707208000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival outcomes and prognostic factors in de novo advanced biliary tract cancer: insights from a Saudi multicenter cohort"],"prefix":"10.3389","volume":"16","author":[{"given":"Bader","family":"Alshamsan","sequence":"first","affiliation":[{"name":"Department of Medicine, College of Medicine, Qassim University","place":["Qassim, Saudi Arabia"]},{"name":"Prince Faisal Cancer Center, King Fahad Specialist Hospital, Qassim Health Cluster","place":["Buraydah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Tashkandi","sequence":"additional","affiliation":[{"name":"College of Medicine, Umm Al-Qura University","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"Oncology Center, King Saud University Medical City, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali H.","family":"Alfakeeh","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Medical Oncology, King Fahad Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali M.","family":"Alzahrani","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Medical Oncology, King Fahad Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulhameed H.","family":"Alfagih","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Medical Oncology, King Fahad Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Alkaiyat","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, King Abdulaziz Medical City, Ministry of National Guard for Health Affairs","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Zia Ul","family":"Hasan","sequence":"additional","affiliation":[{"name":"Prince Faisal Cancer Center, King Fahad Specialist Hospital, Qassim Health Cluster","place":["Buraydah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam","family":"Shehata","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, King Abdulaziz Medical City, Ministry of National Guard for Health Affairs","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reham","family":"Alghandour","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, King Abdullah Medical City","place":["Makkah, Saudi Arabia"]},{"name":"Medical Oncology Department, Oncology Center, Mansoura University","place":["Mansoura, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Zuhdy","sequence":"additional","affiliation":[{"name":"Surgical Oncology Department, King Abdullah Medical City","place":["Makkah, Saudi Arabia"]},{"name":"Surgical Oncology Department, Oncology Center, Mansoura University","place":["Mansoura, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abdelhalim","sequence":"additional","affiliation":[{"name":"Prince Faisal Cancer Center, King Fahad Specialist Hospital, Qassim Health Cluster","place":["Buraydah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Algarni","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, King Abdulaziz Medical City, Ministry of National Guard for Health Affairs","place":["Riyadh, Saudi Arabia"]},{"name":"Department of Medicine, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanan","family":"Alshammari","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, King Abdulaziz Medical City, Ministry of National Guard for Health Affairs","place":["Riyadh, Saudi Arabia"]},{"name":"Department of Medicine, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers16091761","article-title":"Recent advancement in diagnosis of biliary tract cancer through pathological and molecular classifications","volume":"16","author":"Lee","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1384314","article-title":"Global, regional, and national burden and trends analysis of gallbladder and biliary tract cancer from 1990 to 2019 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2019","volume":"11","author":"Su","year":"2024","journal-title":"Front Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33476","article-title":"The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"127","author":"Ouyang","year":"2021","journal-title":"Cancer"},{"key":"B7","unstructured":"Cancer incidence report: Saudi Arabia 2022\n          \n          \n          Saudi Arabia\n          Saudi Health Council\n          Saudi health council\n          \n          2022"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/evidoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"B10","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2025","journal-title":"ESMO Open"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2021-003214","article-title":"Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes","volume":"9","author":"Chen","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.02.015","article-title":"Neutrophil\/lymphocyte ratio as a prognostic factor in biliary tract cancer","volume":"50","author":"McNamara","year":"2014","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2078-6891.2014.081","article-title":"A population based analysis of prognostic factors in advanced biliary tract cancer","volume":"5","author":"Peixoto","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000453084","article-title":"Systemic therapy of cholangiocarcinoma","volume":"32","author":"Plentz","year":"2016","journal-title":"Visc Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv483","article-title":"Prognostic factors for progression-free and overall survival in advanced biliary tract cancer","volume":"27","author":"Bridgewater","year":"2016","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2021.1953887","article-title":"Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis","volume":"34","author":"Filippi","year":"2022","journal-title":"J Chemother"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"4","author":"Von Elm","year":"2007","journal-title":"PloS Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2025.100152","article-title":"Intrahepatic cholangiocarcinoma trends and treatment lines: real-world evidence from the French National Hospital Discharge database","volume":"8","author":"Delaye","year":"2025","journal-title":"ESMO Gastrointest Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6892","article-title":"Treatments, prognostic factors, and genetic heterogeneity in advanced cholangiocarcinoma: a multicenter real-world study","volume":"13","author":"Ottaiano","year":"2024","journal-title":"Cancer Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2379237","article-title":"Real-world treatment patterns, resource utilization and costs in biliary tract cancers in the USA","volume":"20","author":"Wang","year":"2024","journal-title":"Future Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41598-022-13605-3","article-title":"Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study","volume":"12","author":"Kang","year":"2022","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1186\/S12876-022-02637-8","article-title":"The epidemiological trends of biliary tract cancers in the United States of America","volume":"22","author":"Jiang","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.08.032","article-title":"Age trends in biliary tract cancer incidence by anatomical subtype: A Swedish cohort study","volume":"175","author":"Rahman","year":"2022","journal-title":"Eur J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastha.2022.04.007","article-title":"Worldwide incidence and mortality of biliary tract cancer","volume":"1","author":"Baria","year":"2022","journal-title":"Gastro Hep Adv"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers16152720","article-title":"Incidence and long-term outcomes of biliary tract cancers in Olmsted County, Minnesota from 1976 to 2018","volume":"16","author":"Nwankwo","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000343","article-title":"Adolescent and young adult cancer biology","volume":"24","author":"Tricoli","year":"2018","journal-title":"Cancer J (United States)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00594","article-title":"The Cholangiocarcinoma in the Young (CITY) Study: Tumor biology, treatment patterns, and survival outcomes in adolescent young adults with cholangiocarcinoma","volume":"7","author":"Pappas","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.5009\/GNL18105","article-title":"Incidence and overall survival of biliary tract cancers in South Korea from 2006 to 2015: Using the National Health Information Database","volume":"13","author":"Kim","year":"2019","journal-title":"Gut Liver"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/S41416-023-02460-2","article-title":"Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy","volume":"129","author":"d\u2019Abrigeon","year":"2023","journal-title":"Br J Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11072057","article-title":"Impact of liver fibrosis on survival of patients with intrahepatic cholangiocarcinoma receiving gemcitabine-based chemotherapy","volume":"11","author":"Kinzler","year":"2022","journal-title":"J Clin Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12876-023-02710-W","article-title":"Cirrhosis in intrahepatic cholangiocarcinoma: prognostic importance and impact on survival","volume":"23","author":"Thakral","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"996","DOI":"10.21037\/JGO.2016.09.10","article-title":"Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States","volume":"7","author":"Agarwal","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/CNCR.24472","article-title":"Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy","volume":"115","author":"Park","year":"2009","journal-title":"Cancer"},{"key":"B38","doi-asserted-by":"crossref","unstructured":"Recent 5-year trends in biliary tract cancer survival rates: an analytical big data survey\n          \n          \n            \n              Lee\n              JY\n            \n            \n              Ku\n              JL\n            \n            \n              Kim\n              JW\n            \n          \n          10.3892\/mco.2025.2839\n          Mol Clin Oncol\n          22\n          2025","DOI":"10.3892\/mi.2025.214"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00534-008-0015-0","article-title":"Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan","volume":"16","author":"Miyakawa","year":"2009","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"B40","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.21037\/CCO-22-93","article-title":"Targeted therapies in advanced biliary tract cancers\u2014a narrative review","volume":"12","author":"LaPelusa","year":"2023","journal-title":"Chin Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101171","article-title":"Mapping the landscape of biliary tract cancer in Europe: challenges and controversies","volume":"50","author":"Rimassa","year":"2025","journal-title":"Lancet Reg Heal - Eur"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3748\/WJG.V31.I11.104170","article-title":"Cholangiocarcinoma: The era of liquid biopsy","volume":"31","author":"Kotsifa","year":"2025","journal-title":"World J Gastroenterol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1712037\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:26:51Z","timestamp":1782707211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1712037\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":43,"alternative-id":["10.3389\/fonc.2026.1712037"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1712037","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"article-number":"1712037"}}